ATTO Attovia Therapeutics, Inc.

Moderna (MRNA) stock rose roughly 510% over the year to September 21, 2026, climbing from about $25 to about $173. The S&P 500 gained 18.5% with dividends reinvested over the same window, and Pfizer (PFE) about 23%. The run's central event came on August 19, 2026, when Merck and Moderna said a Phase III trial of their cancer vaccine, intismeran autogene, met its endpoints in melanoma. A rough timetable for the trial was public long before the stock moved, but its result was not.

Attovia Therapeutics (ATTO) has been drawing attention after a recent pullback, with the share price closing at US$21.30. The move comes as investors weigh performance in immune-mediated disease programs and current valuation. Short term sentiment around Attovia Therapeutics has cooled, with the 1-day share price return down 3.79% and the 7-day share price return down 13.13%. The 30-day share price return is up 2.40% and the year-to-date share price return is down 2.74%, which points to...

Attovia Therapeutics' (ATTO) ATTOBODY platform should position the company as a key player in immuno

Deere upgraded, Lumentum initiated: Wall Street's top analyst calls

Rate hike fears rattled markets heading into the Labor Day weekend, and Wall Street analysts responded with a flurry of bold calls on utilities, farm equipment giants, and a ticketing upstart that could reshape your portfolio heading into a volatile fall.

Moderna's commercial business has shrunk and is lossmaking, which puts the weight of its market value on a pipeline rather than on revenue.

Before the melanoma result, the visible signs were an enrolled trial, a partner paying half its cost, and a market that had stopped pricing an unusually large move.

The trial met both endpoints in the readout, removing the inconclusive outcome management itself had flagged, and short sellers in the stock took a record single-session loss.

A newly public biotech is betting its entire future on a single antibody platform designed to silence the cytokine scientists call the itch cytokine, and its pipeline already stretches from skin disease into inflammatory bowel disease.